Filtered By:
Source: The American Journal of Cardiology
Condition: Thrombosis

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 75 results found since Jan 2013.

Procedural and Short-Term Outcomes of Percutaneous Left Atrial Appendage Closure in Patients with Cancer
Percutaneous left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific) has emerged as an alternative to anticoagulation in patients with atrial fibrillation (AF). Cancer is a common comorbidity in patients with AF (1,2). Also, AF patients with cancer reportedly have a higher bleeding risk with a similar or higher stroke risk than those without cancer (3). Thus, AF patients with cancer unsuitable for anticoagulation can be indicated for LAAC to prevent AF-related thromboembolism (2).
Source: The American Journal of Cardiology - December 3, 2020 Category: Cardiology Authors: Toshiaki Isogai, Anas M. Saad, Abdelrahman Ibrahim Abushouk, Shashank Shekhar, Shunsuke Kuroda, Mohamed M. Gad, Oussama M. Wazni, Amar Krishnaswamy, Samir R. Kapadia Source Type: research

Meta-Analysis of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valves
Valvular heart disease is frequently complicated by atrial fibrillation, which is associated with an increased risk of mortality. In the presence of a surgical or transcatheter bioprosthetic valve, patients with atrial fibrillation are at increased risks of systemic thromboembolism.1 Although direct oral anticoagulants (DOACs) have been shown to be non-inferior or superior to warfarin in preventing stroke or thromboembolism associated with nonvalvular atrial fibrillation, the utilization of DOACs in patients with prior bioprosthetic valves has been limited in randomized clinical trials (RCTs).
Source: The American Journal of Cardiology - December 3, 2020 Category: Cardiology Authors: Babikir Kheiri, Ryle Przybylowicz, Timothy F Simpson, Hani Alhamoud, Mohammed Osman, Khidir Dalouk, Babak Nazer, Charles A. Henrikson, Eric Stecker Source Type: research

Meta-Analysis of Bioprosthetic Valve Thrombosis after Transcatheter Aortic Valve Implantation
Bioprosthetic valve thrombosis may complicate transcatheter aortic valve implantation (TAVI). This meta-analysis sought to evaluate the prevalence and clinical impact of subclinical leaflet thrombosis (SLT) and clinical valve thrombosis (CVT) after TAVI. We summarized diagnostic strategies, prevalence of SLT and/or CVT and estimated their impact on the risk of all-cause death and stroke. Twenty studies with 12,128 patients were included. The prevalence of SLT and CVT was 15.1% and 1.2%, respectively.
Source: The American Journal of Cardiology - October 12, 2020 Category: Cardiology Authors: Tobias Rheude, Costanza Pellegrini, Stefan Stortecky, Mohamed Marwan, Erion Xhepa, Fabian Ammon, Thomas Pilgrim, N. Patrick Mayr, Oliver Husser, Stephan Achenbach, Stephan Windecker, Salvatore Cassese, Michael Joner Source Type: research

Dose of Direct Oral Anticoagulants and Adverse Outcomes in Asia
One of the main purposes in the treatment of patients with atrial fibrillation (AF) is the prevention of stroke or systemic embolism. In the current clinical practice, direct oral anticoagulants (DOACs) have been approved for thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF). Each DOAC has specific dose reduction criteria considering age, renal function, body weight, and concomitant medications. A previous report from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II [ORBIT-AF II] showed that a significant minority (almost 1 in 8) of U.S.
Source: The American Journal of Cardiology - October 12, 2020 Category: Cardiology Authors: Junichi Ohno, Yohei Sotomi, Akio Hirata, Yasushi Sakata, Atsushi Hirayama, Yoshiharu Higuchi Source Type: research

Temporal Trends and Outcomes of Left Ventricular Aneurysm after Acute Myocardial Infarction
There are limited data on the prevalence and an outcome of left ventricular (LV) aneurysms following acute myocardial infarction (AMI). Using the National Inpatient Sample during 2000-2017, a retrospective cohort of AMI admissions was evaluated for LV aneurysms. Complications included ventricular arrhythmias, mechanical, cardiac arrest, pump failure, LV thrombus, and stroke. Outcomes of interest included in-hospital mortality, temporal trends, complications, hospitalization costs, and length of stay.
Source: The American Journal of Cardiology - July 26, 2020 Category: Cardiology Authors: Saraschandra Vallabhajosyula, Siddak Kanwar, Htin Aung, Wisit Cheungpasitporn, Claire E Raphael, Rajiv Gulati, Mandeep Singh Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It affects 1 in 4 adults aged>40 years,1 and is associated with a 5-fold increased risk of stroke.1 Hence, anticoagulants are universally recommended to prevent stroke and systemic embolism in patients with AF.1 The non-vitamin K antagonist oral anticoagulants (NOACs) are important alternatives to warfarin for prevention of arterial thromboembolism in patients with AF. Currently, the FDA has approved four NOACs for use in patients with AF: dabigatran is a thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are factor Xa inhibitors.
Source: The American Journal of Cardiology - April 22, 2020 Category: Cardiology Authors: Stephen Y Wang, Robert P Giugliano Tags: Review Article Source Type: research

The Interaction Among Atrial Thromboembolism, Atrial Fibrillation, and Atrial Cardiomyopathy
I read with interest the timely paper titled “Thromboembolism in the Absence of Atrial Fibrillation” by Smietana et al1 that discusses several highly important but underappreciated contributors to ischemic stroke in patients with and without atrial fibrillation (AF). Several are worthy of further emphasis and/or expansion for your readers, both investigators and clinicians. First is the recognition of the concept of atrial cardiomyopathy.2 Atrial cardiomyopathy may be a cause and/or consequence of AF; can vary with the etiology, duration, number, and severity of associated comorbidities as well as the amount of AF pres...
Source: The American Journal of Cardiology - August 1, 2019 Category: Cardiology Authors: James A. Reiffel Source Type: research

Meta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy After Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy Treatment
The patient's profile drawing the greatest benefit from dual antiplatelet therapy (DAPT) after a non-cardioembolic, ischemic cerebrovascular event is not well characterized. Aim of this meta-regression analysis was to compare DAPT versus single antiplatelet therapy (SAPT) in patients with stroke or transient ischemic attack (TIA). We searched randomized trials evaluating clinical outcome with aspirin plus a P2Y12 inhibitor versus SAPT in patients with non-cardioembolic stroke or TIA. Primary endpoint was the incidence of recurrent stroke; safety outcome measure was major bleeding.
Source: The American Journal of Cardiology - May 24, 2019 Category: Cardiology Authors: Giuseppe Patti, Alessandro Sticchi, Antonio Bisignani, Francesco Pelliccia, Vincenzo Pasceri, Giulio Speciale, Maria Penco Source Type: research

Thromboembolism In The Absence Of Atrial Fibrillation
Atrial fibrillation (AF) is associated with thrombus formation in the left atrial appendage (LAA) and systemic embolic events including ischemic stroke. Cardiogenic thromboembolism can also occur in the absence of clinical AF as a result of various pathological conditions affecting the endocardium. The inconsistent temporal relation between AF and ischemic events has stimulated exploration for factors other than clinical AF that contribute to thromboembolism. These include sub-clinical AF, a thrombogenic atrial cardiomyopathy, LAA dysfunction and embolism from other sources.
Source: The American Journal of Cardiology - April 23, 2019 Category: Cardiology Authors: Jeffrey Smietana, Anna Plitt, Jonathan L. Halperin Source Type: research

Reader's Comments: Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism
I read with great interest the paper by Zhang et al1 in which the authors reported that the incidence of stroke and systemic embolism and overall mortality were lower in paroxysmal atrial fibrillation (AF) than in persistent or permanent AF while annualized major bleeding rates were similar across AF types. In truth, this is not a new observation. Ganesan et al2 reported essentially the same findings in 2016, as have others.3 Importantly, Zhang et al1 noted that both the CHADS2 and CHA2DS2-VASc risk scoring systems do not consider the type of AF, which may be a significant limitation in their utility if AF type is truly im...
Source: The American Journal of Cardiology - April 8, 2019 Category: Cardiology Authors: James A. Reiffel Source Type: research

Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism
I read with great interest the paper by Zhang and colleagues1 in which the authors reported that the incidence of stroke and systemic embolism and overall mortality were lower in paroxysmal atrial fibrillation (AF) than in persistent or permanent AF while annualized major bleeding rates were similar across AF types. In truth, this is not a new observation. Ganesan et al.2 reported essentially the same findings in 2016, as have others.3 Importantly, Zhang et al.1 noted that both the CHADS2 and CHA2DS2-VASc risk scoring systems do not consider the type of AF, which may be a significant limitation in their utility if AF type ...
Source: The American Journal of Cardiology - April 8, 2019 Category: Cardiology Authors: James A. Reiffel Tags: Reader's Comments Source Type: research

Cardiovascular Outcomes and All-cause Mortality Following Measurement of Endogenous Testosterone Levels
We examined whether low total testosterone levels are associated with stroke (ischemic and hemorrhagic), myocardial infarction (MI), venous thromboembolism (VTE), and all-cause mortality among adult men. We conducted a cohort study in the Central Denmark Region (20002015). We included all men with a first-ever laboratory testosterone result and computed the 5-year risks of cardiovascular outcomes and all-cause mortality.
Source: The American Journal of Cardiology - March 7, 2019 Category: Cardiology Authors: Kasper Adelborg, Thomas B øjer Rasmussen, Helene Nørrelund, J Bradley Layton, Henrik Toft Sørensen, Christian Fynbo Christiansen Source Type: research

Relation of Venous Thromboembolism Risk to Ischemic Stroke Risk in Hospitalized Patients with Cancer
Patients with cancer are at increased risk for venous thromboembolism (VTE). However, the relationship of cancer type to the risk of arterial thrombosis in patients with high VTE risk has not been described. The goal of this study is to determine the rate of arterial thrombosis in patients with different types of solid tumors stratified by VTE risk. Using the 2012 National Inpatient Sample, we identified 373,789 hospitalizations involving patients ≥18 years associated with solid tumors, stratified by type.
Source: The American Journal of Cardiology - November 24, 2018 Category: Cardiology Authors: Alyssa M. Corley, Malachy J. Sullivan, Scott E. Friedman, Daniel J. O'Rourke, Robert T. Palac, Anthony S. Gemignani Source Type: research

Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation
This study sought to establish 1) the prevalence of LAA thrombus 2) the prevalence of LAA thrombus despite antithrombotic therapy, 3) the rate of persistence of LAA thrombus despite appropriate anticoagulant prescriptions, and 4) determinants of LAA thrombus persistence.
Source: The American Journal of Cardiology - September 26, 2018 Category: Cardiology Authors: Adam D Niku, Takahiro Shiota, Robert J Siegel, Florian Rader Source Type: research

Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With A Mechanical Prosthesis
Rivaroxaban has previously been tested in experimental and animal models with encouraging results. We prospectively selected 7 patients between May 2017 and January 2018 who underwent isolated mitral valve replacement with a mechanic prosthesis and had unstable INR control at least 3 months after surgery. An intervention of rivaroxaban 15 mg was then administered twice daily for a period of 90 days. No patient presented intracardiac thrombus, reversible ischemic neurological deficit, ischemic or hemorrhagic stroke, hospitalization or death during 3 months of follow-up.
Source: The American Journal of Cardiology - July 15, 2018 Category: Cardiology Authors: Andr é R Durães, Yasmin de S L Bitar, Maria Luiza G Lima, Caroline C Santos, Igor S Schonhofen, José Admirço L Filho, Leonardo Roever Source Type: research